The FDA announced today that it has sent warning letters to 30 telehealth companies over the marketing of compounded GLP-1 drugs — versions of semaglutide and tirzepatide made by compounding pharmacies rather than the manufacturers. The agency objects to two things: ads implying the compounded product is the same as the FDA-approved drug, and ads that put the telehealth company's own brand on a drug it did not make. It is the second batch of such letters since September, and the agency says it has sent thousands of notices to drug and telehealth firms about misleading ads in six months. The commissioner's line was "It's a new era." The business line, for anyone who has watched the longevity industry, is older than that.
Why 'same' is the whole argument. An approved drug has been through trials, inspections and a label; a compounded drug has been made by a pharmacy, legally, for a patient's specific need, with none of that review. It may be fine. The point is that nobody checked, and an ad that says "same" borrows a review that did not happen. That is exactly the move we describe when a supplement cites a drug's trial, or a wearable implies a diagnosis: the credibility of evidence attached to a product that did not earn it. Compounders argue that personalized doses are what the law allows; some of that will be litigated. The marketing claim is simpler, and it is what the letters are about.
Ben’s takeThe compounded-GLP-1 business was built in a shortage and priced below the branded drugs, which did real good for people who could not afford the originals. Then the pill arrived at $149 and the price argument got thinner. What is left is the word "same," and the FDA just took it away. Expect the ads to get vaguer and the business to shrink toward what it can prove. That is the right direction, and it is the one the rest of the wellness economy has never had to travel.
Loree’s takeI have patients on compounded versions, and I do not lecture them. I ask what they are taking, at what dose, from whom, and whether anyone is following their labs. The risk in this market is not that compounding exists. It is that a website replaced a clinician, and a brand name replaced a question. A warning letter does not fix that. A person who knows what they are taking does.
Why it matters to a recovering optimizer. Every month this year, medicine and merchandise have been forced to stand closer together — a validated drug at subscription prices, a subscription drug that must now stop claiming to be the drug. The habit that protects you in both aisles is the same: ask who checked. For an approved drug, the answer is written on the label. For everything else, the answer is usually the seller.
When an ad says "same as," ask who checked. If the answer is the seller, it isn't the same.
This post reports on evidence and expert disagreement. It is not medical advice; decisions about treatment belong with you and your clinician.